ICU Medical, Inc. $ICUI Shares Sold by Boston Trust Walden Corp

Key Points

• Boston Trust Walden Corp reduced its stake in ICU Medical by 44.0% in the second quarter, selling 95,313 shares for a total of 121,352 shares now held.
• ICU Medical reported a Q2 EPS of $2.10, exceeding the analysts' expectations of $1.44, while revenue decreased by 8.0% year-over-year.
• Recent insider transactions include CEO Vivek Jain purchasing 21,929 shares at an average price of $112.84, increasing his stake by 20.26%.

Boston Trust Walden Corp decreased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 44.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 121,352 shares of the medical instruments supplier's stock after selling 95,313 shares during the quarter. Boston Trust Walden Corp owned 0.49% of ICU Medical worth $16,037,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 153 shares during the period. SG Americas Securities LLC acquired a new position in ICU Medical in the first quarter valued at approximately $859,000. Vontobel Holding Ltd. acquired a new position in ICU Medical in the first quarter valued at approximately $235,000. EP Wealth Advisors LLC acquired a new position in ICU Medical in the first quarter valued at approximately $479,000. Finally, Vident Advisory LLC acquired a new position in ICU Medical in the first quarter valued at approximately $270,000. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Stock Up 0.9%

ICU Medical stock opened at $117.31 on Wednesday. The stock has a market capitalization of $2.90 billion, a PE ratio of -77.18 and a beta of 0.83. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26. The business has a 50 day simple moving average of $123.82 and a 200-day simple moving average of $130.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. The business had revenue of $543.57 million during the quarter, compared to analysts' expectations of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The business's revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director David C. Greenberg purchased 1,200 shares of the company's stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director owned 7,960 shares of the company's stock, valued at $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Vivek Jain purchased 21,929 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the transaction, the chief executive officer directly owned 130,149 shares of the company's stock, valued at $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ICUI has been the subject of a number of analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of ICU Medical in a report on Wednesday, October 8th. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th. Raymond James Financial decreased their price target on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a report on Friday, August 8th. Finally, Piper Sandler boosted their price target on ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a report on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $181.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.